|
Juvenile Myelomonocytic Leukemia
|
0.510 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of juvenile myelomonocytic leukemia.
|
26457647 |
2015 |
|
Noonan Syndrome
|
0.510 |
GeneticVariation
|
disease |
BEFREE |
We report on two germline mutations (p.Gly39dup and p.Val55Met) in RRAS, a gene encoding a small monomeric GTPase controlling cell adhesion, spreading and migration, underlying a rare (2 subjects among 504 individuals analysed) and variable phenotype with features partially overlapping Noonan syndrome, the most common RASopathy.
|
24705357 |
2014 |
|
Noonan Syndrome
|
0.510 |
Biomarker
|
disease |
CLINGEN |
We report on two germline mutations (p.Gly39dup and p.Val55Met) in RRAS, a gene encoding a small monomeric GTPase controlling cell adhesion, spreading and migration, underlying a rare (2 subjects among 504 individuals analysed) and variable phenotype with features partially overlapping Noonan syndrome, the most common RASopathy.
|
24705357 |
2014 |
|
Noonan Syndrome
|
0.510 |
GeneticVariation
|
disease |
ORPHANET |
We report on two germline mutations (p.Gly39dup and p.Val55Met) in RRAS, a gene encoding a small monomeric GTPase controlling cell adhesion, spreading and migration, underlying a rare (2 subjects among 504 individuals analysed) and variable phenotype with features partially overlapping Noonan syndrome, the most common RASopathy.
|
24705357 |
2014 |
|
Juvenile Myelomonocytic Leukemia
|
0.510 |
GeneticVariation
|
disease |
ORPHANET |
We also identified somatic RRAS mutations (p.Gly39dup and p.Gln87Leu) in 2 of 110 cases of non-syndromic juvenile myelomonocytic leukaemia, a childhood myeloproliferative/myelodysplastic disease caused by upregulated RAS signalling, defining an atypical form of this haematological disorder rapidly progressing to acute myeloid leukaemia.
|
24705357 |
2014 |
|
Juvenile Myelomonocytic Leukemia
|
0.510 |
GeneticVariation
|
disease |
BEFREE |
We also identified somatic RRAS mutations (p.Gly39dup and p.Gln87Leu) in 2 of 110 cases of non-syndromic juvenile myelomonocytic leukaemia, a childhood myeloproliferative/myelodysplastic disease caused by upregulated RAS signalling, defining an atypical form of this haematological disorder rapidly progressing to acute myeloid leukaemia.
|
24705357 |
2014 |
|
Noonan Syndrome
|
0.510 |
Biomarker
|
disease |
CLINGEN |
The RASopathies.
|
23875798 |
2013 |
|
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical studies have demonstrated increased p23 expression in advanced prostate cancer.
|
25241147 |
2015 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
In human prostate tumors, nuclear p23 was higher in malignant prostate cells compared with benign/normal cells, supporting the utility of p23 as a therapeutic target in prostate cancer.
|
22899854 |
2012 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
These results highlight a previously uncharacterized subfamily of Ras-related genes that may have a tumor suppressor role in prostate cancer.
|
15033445 |
2004 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
The 8p22 through p23 region has been identified as a potential site for genes associated with prostate cancer.
|
12377406 |
2002 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
|
LEOPARD Syndrome
|
0.300 |
Biomarker
|
disease |
CLINGEN |
|
|
|
|
Costello syndrome (disorder)
|
0.300 |
Biomarker
|
disease |
CLINGEN |
|
|
|
|
Cardio-facio-cutaneous syndrome
|
0.300 |
Biomarker
|
disease |
CLINGEN |
|
|
|
|
Noonan syndrome-like disorder with loose anagen hair
|
0.300 |
Biomarker
|
disease |
CLINGEN |
|
|
|
|
Noonan-Like Syndrome With Loose Anagen Hair
|
0.300 |
Biomarker
|
disease |
CLINGEN |
|
|
|
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression levels of this receptor protein is sensitive to the cellular p23 protein levels in immortalized cancer cell lines.
|
30204910 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hence, these results supported the fact that green tea contained potential compounds with an ability to inhibit the cancer by disrupting the co-chaperon p23 activity.
|
31257629 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Ras-related gene ERAS is involved in human and murine breast cancer.
|
30158566 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A thirty-year quest for a role of R-Ras in cancer: from an oncogene to a multitasking GTPase.
|
28610953 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Rho GTPases Rac (Ras-related C3 botulinum toxin substrate) and Cdc42 (cell division control protein 42 homolog) regulate cell functions governing cancer malignancy, including cell polarity, migration, and cell-cycle progression.
|
28450422 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RAB23, a member of Ras-related small GTPase family, has been reported to be up-regulated in several cancer types.
|
27659550 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, these data support that RASA1 is inactivated by mutation or by suppressed expression in melanoma and that RASA1 plays a tumor suppressive role by inhibiting R-Ras, a previously less appreciated member of the Ras small GTPases.
|
26993606 |
2016 |